No-Reflow Phenomenon: Clinical Trials

3 trials for No-Reflow Phenomenon, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 not yet recruiting. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 1, Completed 1, Not yet recruiting 1
Phase 11Completed 1

Follow No-Reflow Phenomenon: new trials by email Literature Review of No-Reflow Phenomenon trials Research Report on No-Reflow Phenomenon

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment - No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Phase 2Not yet recruitingAl-Azhar University1002027-01-012026-10-27
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Empagliflozin 25 milgrams (Mg), Empagliflozin 10 Mg - STEMI, No-Reflow Phenomenon
Phase 2Active not recruitingInstituto Nacional de Cardiologia Ignacio Chavez1622024-08-222026-04-15
Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI
Nicorandil 20mg - No Reflow Phenomenon, Anterior STEMI
Phase 1 / Phase 2CompletedAin Shams University3002024-03-102025-08-24

Narrower conditions

ST Elevation Myocardial Infarction (2)  ·  Coronary Artery Disease (1)  ·  Myocardial Infarction (1)  ·  Myocardial Reperfusion Injury (1)

Broader conditions

Ischemia (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Cardiovascular Diseases (2)  ·  Heart Diseases (2)  ·  Infarction (2)  ·  Myocardial Ischemia (2)  ·  Necrosis (2)  ·  Vascular Diseases (2)  ·  Arterial Occlusive Diseases (1)  ·  Arteriosclerosis (1)  ·  Cardiomyopathies (1)  ·  Coronary Disease (1)  ·  Myocardial Infarction (1)  ·  Postoperative Complications (1)

Interventions

empagliflozin (2)  ·  Nicorandil (1)  ·  dapagliflozin (1)

Sponsors

Ain Shams University (1)  ·  Al-Azhar University (1)  ·  Instituto Nacional de Cardiologia Ignacio Chavez (1)

Countries

Egypt (2)  ·  Mexico (1)

Top investigators

Eduardo Arias-Sanchez, MD (1)

Results publications

PMID 30992077, PMID 31127491, PMID 31759100, PMID 31779619, PMID 32396609, PMID 32539724, PMID 32717242, PMID 34712142, PMID 34896968, PMID 35705980, PMID 41230400